BACKGROUND: We evaluated the longitudinal association of alcohol use with immunologic response to combination antiretroviral therapy (ART) among HIV-infected individuals. METHODS: This was a prospective cohort study of individuals initiating ART. Participants underwent an Audio Computer-Assisted Self-interview querying drug and alcohol use within 6 months of treatment. Immunologic response to ART was defined by CD4 T-cell count (CD4). Primary independent variables were self-reported number of drinks consumed per drinking day (quantity) and days of alcohol consumption in a typical week (frequency). We used linear mixed effects models to quantify the association between CD4 T-cell count and alcohol quantity and frequency and Cox proportional hazards models to estimate the relative hazard of an increase in 100, 150, and 200 CD4 cells per cubic millimeter per additional drink per drinking day. Analyses were stratified by sex. Viral suppression was examined as a time-varying covariate. RESULTS: Between 2000 and 2008, 1107 individuals were eligible for inclusion in this study. There was no statistically significant difference in CD4 T-cell count by average drinks per drinking day at any frequency of alcohol use irrespective of sex or viral suppression. Similarly, we found no difference in the hazard ratio for drinks per drinking day within the categories of drinking frequency for time to CD4 T-cell count increase of 100, 150, and 200 cells per cubic millimeter, respectively. CONCLUSIONS: Among individuals initiating ART, the benefits of therapy and viral suppression on the immune system outweigh detrimental effects of alcohol, reinforcing the importance of initiating ART and ensuring adequate adherence to therapy.
BACKGROUND: We evaluated the longitudinal association of alcohol use with immunologic response to combination antiretroviral therapy (ART) among HIV-infected individuals. METHODS: This was a prospective cohort study of individuals initiating ART. Participants underwent an Audio Computer-Assisted Self-interview querying drug and alcohol use within 6 months of treatment. Immunologic response to ART was defined by CD4 T-cell count (CD4). Primary independent variables were self-reported number of drinks consumed per drinking day (quantity) and days of alcohol consumption in a typical week (frequency). We used linear mixed effects models to quantify the association between CD4 T-cell count and alcohol quantity and frequency and Cox proportional hazards models to estimate the relative hazard of an increase in 100, 150, and 200 CD4 cells per cubic millimeter per additional drink per drinking day. Analyses were stratified by sex. Viral suppression was examined as a time-varying covariate. RESULTS: Between 2000 and 2008, 1107 individuals were eligible for inclusion in this study. There was no statistically significant difference in CD4 T-cell count by average drinks per drinking day at any frequency of alcohol use irrespective of sex or viral suppression. Similarly, we found no difference in the hazard ratio for drinks per drinking day within the categories of drinking frequency for time to CD4 T-cell count increase of 100, 150, and 200 cells per cubic millimeter, respectively. CONCLUSIONS: Among individuals initiating ART, the benefits of therapy and viral suppression on the immune system outweigh detrimental effects of alcohol, reinforcing the importance of initiating ART and ensuring adequate adherence to therapy.
Authors: Gerald N DeLorenze; Constance Weisner; Ai-Lin Tsai; Derek D Satre; Charles P Quesenberry Journal: Alcohol Clin Exp Res Date: 2010-11-08 Impact factor: 3.455
Authors: Musie Ghebremichael; Elijah Paintsil; Jeannette R Ickovics; David Vlahov; Paula Schuman; Robert Boland; Ellie Schoenbaum; Janet Moore; Heping Zhang Journal: AIDS Care Date: 2009-07
Authors: Christian S Hendershot; Susan A Stoner; David W Pantalone; Jane M Simoni Journal: J Acquir Immune Defic Syndr Date: 2009-10-01 Impact factor: 3.731
Authors: Heidi E Hutton; Mary E McCaul; Geetanjali Chander; Mollie W Jenckes; Christine Nollen; Victoria L Sharp; Emily J Erbelding Journal: AIDS Behav Date: 2013-06
Authors: Robert G Deiss; Octavio Mesner; Brian K Agan; Anuradha Ganesan; Jason F Okulicz; Mary Bavaro; Tahaniyat Lalani; Thomas A O'Bryan; Ionut Bebu; Grace E Macalino Journal: Alcohol Clin Exp Res Date: 2016-02-25 Impact factor: 3.455
Authors: Rupak Shivakoti; Erin R Ewald; Nikhil Gupte; Wei-Teng Yang; Cecilia Kanyama; Sandra W Cardoso; Breno Santos; Khuanchai Supparatpinyo; Sharlaa Badal-Faesen; Javier R Lama; Umesh Lalloo; Fatima Zulu; Jyoti S Pawar; Cynthia Riviere; Nagalingeswaran Kumarasamy; James Hakim; Richard Pollard; Barbara Detrick; Ashwin Balagopal; David M Asmuth; Richard D Semba; Thomas B Campbell; Jonathan Golub; Amita Gupta Journal: Clin Nutr Date: 2018-05-29 Impact factor: 7.324
Authors: Anthony Cagle; Christine McGrath; Barbra A Richardson; Dennis Donovan; Sameh Sakr; Nelly Yatich; Richard Ngomoa; Agnes Chepngeno Langat; Grace John-Stewart; Michael H Chung Journal: AIDS Care Date: 2017-01-29
Authors: Usama Bilal; Bryan Lau; Mariana Lazo; Mary E McCaul; Heidi E Hutton; Mark S Sulkowski; Richard D Moore; Geetanjali Chander Journal: AIDS Patient Care STDS Date: 2016-05 Impact factor: 5.078
Authors: Emily C Williams; Judith A Hahn; Richard Saitz; Kendall Bryant; Marlene C Lira; Jeffrey H Samet Journal: Alcohol Clin Exp Res Date: 2016-09-22 Impact factor: 3.455
Authors: Panagiotis Vagenas; Marwan M Azar; Michael M Copenhaver; Sandra A Springer; Patricia E Molina; Frederick L Altice Journal: Curr HIV/AIDS Rep Date: 2015-12 Impact factor: 5.071